QLGN: שווי חברה לרווח נקי Qualigen Corp

This daily price chart for Qualigen Therapeutics (QLGN) on the GURU.Markets platform reflects a value of -1.20. The business relies on FastPack AI platforms for the automated discovery of biomarkers without human intervention. However, geopolitical fragmentation and trade barriers are reducing export revenues. Consequently, management is cutting ancillary projects, redirecting available funds toward the development of its oncology profile.

The P/E ratio determines the cost of one unit of net profit, reflecting market expectations for the asset's return. By analyzing the estimated P/E of a company, an investor can discern actual capital density and overvaluation risks. The metric is calculated as the ratio of the current share price to the annual earnings per share. For Qualigen Therapeutics (QLGN), this trend is critical, as the business focuses on costly oncology developments. High values here typically reflect the market's confidence in the future commercialization of innovative diagnostic platforms.